VA Medical Center and UCSF

3 ARTICLES PUBLISHED IN JoVE

Medicine

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Nathan Bucay¹, Varahram Shahryari¹, Shahana Majid¹, Soichiro Yamamura¹, Yozo Mitsui¹, Z. Laura Tabatabai¹, Kirsten Greene¹, Guoren Deng¹, Rajvir Dahiya¹, Yuichiro Tanaka¹, Sharanjot Saini¹

¹Department of Urology, Veterans Affairs Medical Center, San Francisco, University of California San Francisco

Here we describe a simplified protocol for microRNA (miRNA) expression analyses in archived Formalin-Fixed, Paraffin-Embedded (FFPE) or fresh frozen prostate cancer (PCa) clinical tissues employing quantitative real-time PCR (RT-PCR) and in situ hybridization (ISH).

Medicine

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Varahram Shahryari¹, Hannah Nip¹, Sharanjot Saini¹, Altaf A. Dar², Soichiro Yamamura¹, Yozo Mitsui¹, Melissa Colden¹, Nathan Bucay¹, Laura Z. Tabatabai¹, Kirsten Greene¹, Guoren Deng¹, Yuichiro Tanaka¹, Rajvir Dahiya¹, Shahana Majid¹

¹Department of Urology, VA Medical Center and UCSF, ²California Pacific Medical Center Research Institute

Prostate cancer is the second most common cause of cancer-related deaths in the United States. An orthotopic cancer model provides a useful approach to understand the biology of prostate cancer and to evaluate the efficacy of therapeutic regimens. This protocol describes detailed steps necessary to establish an orthotopic prostate cancer mouse model.

Cancer Research

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Divya Bhagirath¹, Rajvir Dahiya², Shahana Majid², Z. Laura Tabatabai³, Sharanjot Saini¹

¹Department of Biochemistry and Molecular Biology, Augusta University, ²Department of Urology, Veterans Affairs Medical Center and University of California, San Francisco, ³Department of Pathology, Veterans Affairs Medical Center and University of California, San Francisco

Therapy resistance often develops in patients with advanced prostate cancer, and in some cases, cancer progresses to a lethal subtype called neuroendocrine prostate cancer. Assessing the small non-coding RNA-mediated molecular changes that facilitate this transition would allow better disease stratification and identification of causal mechanisms that lead to development of neuroendocrine prostate cancer.